Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a 10BSH-containing WOW emulsion

Yanagië, Hironobu; Higashi, Shinji; Seguchi, Koji; Ikushima, Ichiro; Fujihara, Mituteru; Nonaka, Yasunobu; Oyama, Kazuyuki; Maruyama, Syoji; Hatae, Ryo; Suzuki, Minoru; Masunaga, Shin‐ichiro; Kinashi, Tomoko; Sakurai, Yoshinori; Tanaka, Hiroki; Kondo, Natsuko; Narabayashi, Masaru; Kajiyama, Tetsuya; Maruhashi, Akira; Ono, Koji; Nakajima, Jun; Ono, Masahiro; Takahashi, Hiroyuki; Eriguchi, Masazumi

doi:10.1016/j.apradiso.2014.01.014

Cited by 39 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was considered to have stable disease on initial follow-up imaging, although he later developed multiple nodules in the left lobe of the liver as well as lung metastatic disease. The patient died from pneumonia 7 months after BNCT (70).…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget’s disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.

show abstract

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tumor growth suppression was observed using the intraarterial injection of WOW-Epi to hypervascular tumors. We hope to prepare a boron-compound-entrapped WOW (WOW-Boron) and would like to apply intra-arterial chemotherapy techniques using WOW-Boron for boron neutron-capture therapy for hypervascular tumors in the liver in the near future (29)(30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water EmulsionIn Vivo

Yanagië

Fukushima

Yanagawa

et al. 2021

In Vivo

Self Cite

View full text Add to dashboard Cite

“…Of course, this type of therapy is not yet a widely available cancer treatment, and indications for its use are limited. To date, BNCT has been applied to treat the following cancers: glioblastoma multiforme [88], head and neck cancer [89], multifocal hepatocellular carcinoma [90], recurrent lung cancer [91], squamous cell carcinomas, salivary gland carcinomas, sarcomas, recurrent malignant meningioma [92], and extramammary Paget's disease [93]. Experiences with BCNT for cancer treatment are summarized in Table 1.…”

Section: Bnct In Cancer Treatmentmentioning

confidence: 99%

Boron neutron capture therapy: Current status and future perspectives

Дымова

Taskaev

Richter

et al. 2020

Cancer Communications

178

173

View full text Add to dashboard Cite

The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large‐scale screening of new, more specific boron delivery agents.

show abstract

Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a 10BSH-containing WOW emulsion

Cited by 39 publications

References 11 publications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water EmulsionIn Vivo

Boron neutron capture therapy: Current status and future perspectives

Contact Info

Product

Resources

About